Lab Sciences
Top stories summarized by our editors
6/14/2018

Almost 1% of surgery patients who receive transfusions may develop venous thromboembolism within the next 30 days, according to a 751,000-patient study in JAMA Surgery. Further research is needed, but the data support efforts to limit blood transfusions to situations where they are necessary, said lead researcher Dr. Aaron Tobian, director of transfusion medicine at Johns Hopkins Medicine.

Full Story:
HealthDay News
6/14/2018

The SMART, or Sickle and Malaria Accurate Remote Testing, point-of-care technology platform won top honors at the Vodafone Wireless Innovation Project grant competition, and its developers will receive $300,000 over three years to continue their work. The wireless device can be used to diagnose, track and monitor patients with sickle cell disease and malaria in underserved communities and can interpret data in eight minutes.

More Summaries:
Vodafone
6/13/2018

Paraguay has been declared malaria-free, the first country in the Americas to achieve this status in 45 years, according to the World Health Organization. "Success stories like Paraguay's show what is possible. If malaria can be eliminated in one country, it can be eliminated in all countries," said WHO Director-General Tedros Adhanom Ghebreyesus.

Full Story:
Reuters
6/13/2018

Artemis Therapeutics presented data on its lead candidate artemisone, showing the drug effectively prevents human cytomegalovirus replication, at the 2018 annual meeting of the American Society for Microbiology. Artemisone is being developed as a first-in-class CMV treatment but also as a best-in-class malaria treatment.

Full Story:
PharmaBiz (India)
More Summaries:
Artemis Therapeutics, Artemisone, CMV
6/13/2018

Celltrion Healthcare, an affiliate of biopharmaceutical firm Celltrion, revealed that Truxima, or rituximab, a biosimilar for Roche's Mabthera, is being marketed in 18 European countries since its commercial launch in the UK last year. Truxima, an antibody biosimilar, was developed to treat rheumatoid arthritis and non-Hodgkin lymphoma, among other conditions.

6/12/2018

Amgen's supplemental new drug application for the addition of overall survival data to the label of relapsed or refractory multiple myeloma drug Kyprolis, or carfilzomib, was approved by the FDA. The data were from the late-stage ASPIRE study in which the drug, combined with lenalidomide and dexamethasone, significantly reduced the death risk of patients by 21% and extended overall survival by 7.9 months compared with lenalidomide and dexamethasone alone.

Full Story:
StreetInsider
More Summaries:
Amgen, FDA
6/12/2018

Anna Pyayt, assistant professor of chemical and biomedical engineering at the University of South Florida, hit upon the idea of a mobile blood test lab that leverages two advanced technologies. Smartphones with their processing power and excellent cameras and Arduino microcontrollers and quick prototyping allowed her to produce a compact system that closely mimics its much larger counterpart.

Full Story:
ASME
More Summaries:
University of South Florida
6/12/2018

DNA testing of tumor tissue has quickly gained traction to become the new standard of practice for personalizing colorectal cancer treatment, especially for metastatic disease. This piece delves into five guideline statements on specific tumor tissue biomarkers and mismatch repair testing for colorectal tumor tissue.

More Summaries:
metastatic disease
6/11/2018

The CDC said in Morbidity and Mortality Weekly Report that people who inject drugs were 16 times more likely to develop an invasive methicillin-resistant Staphylococcus aureus infection than non-users. MRSA "is on the skin, and as the needle goes into the skin, it brings the bacteria with it," the CDC's Dr. Isaac See said.

More Summaries:
CDC
6/11/2018

FibroGen has completed enrollment for its late-stage study of roxadustat as a treatment for chronic kidney disease-associated anemia in patients who are and are not dependent upon dialysis, with top-line results expected in the first half of 2019.

Full Story:
Seeking Alpha
More Summaries:
FibroGen